Activist DOMA Perpetual Nominates Directors, Demands CEO Replacement & Formal Sale Process for Pacira BioSciences
PCRX sits 22% above its 52-week low of $18.8.
Summary
Activist investor DOMA Perpetual Capital Management, holding a 7.1% stake, has nominated three director candidates and publicly called for the replacement of Pacira BioSciences' CEO and a formal sale of the company.
Key Events · Corporate Governance and Compliance · PCRX
-
Activist Nominates Directors
DOMA Perpetual Capital Management, a beneficial owner of approximately 7.1% of Pacira's outstanding shares, has nominated three highly qualified candidates for election to the Board of Directors.
-
Demands CEO Replacement
DOMA asserts that CEO Frank Lee should be replaced immediately and an interim CEO appointed, citing significant stock underperformance and management failures.
-
Calls for Company Sale
The activist investor urges the Board to immediately engage bankers to proceed with a formal sale process of the company, discontinuing future acquisitions.
-
Criticizes Performance & Compensation
DOMA highlights Pacira's stock being down 56% over the last decade and 68% over the last five years, alongside consistently missed earnings, lowered guidance, and unsustainable executive compensation.
Analysis · PCRX · Life Sciences
This filing details a significant activist campaign by DOMA Perpetual Capital Management, a 7.1% shareholder, against Pacira BioSciences' current management and board. DOMA is demanding the immediate replacement of CEO Frank Lee and a formal process to sell the company, citing years of severe stock underperformance, missed earnings, and excessive executive compensation. The nomination of three new director candidates signals a proxy fight aimed at fundamentally altering the company's leadership and strategic direction. This event introduces substantial uncertainty and pressure on the company, potentially leading to a major strategic shift or a prolonged governance battle.
At the time of this filing, PCRX was trading at $22.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $924.4M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.